Peter MacCallum Cancer Centre
End-Stage Ovarian Cancer Marked by Rampant Treatment Resistance, Multiple Clones
By profiling multiple tumors per patient, researchers found pronounced polyclonal disease and diverse resistance mechanisms in end-stage high-grade serous ovarian carcinoma.
SEngine Organoid Testing Leads to Treatment Change for Two Metastatic Colorectal Cancer Patients
The researchers said their new study supports the clinical utility of their test, which combines genomic and drug screening analyses of organoids to guide cancer treatment.
Genomic Analyses of Metastatic Lesions in Lethal Breast Cancer Reveal Heterogeneity, Evolution
Researchers analyzed the exomes of metastatic tumor samples from patients who died of breast cancer to piece together the genomic evolution.
Q&A: Peter Mac's Ian Campbell on Cancer Genomics, Next-Gen Technologies, and Research in Australia
Premium
Name: Ian Campbell
Title: Associate professor, Peter MacCallum Cancer Centre
Copy Number Analyses ID Gene Tied to Treatment Resistance in Ovarian Cancer
NEW YORK (GenomeWeb News) – An array-based analysis by researchers from Australia and elsewhere has identified a gene that is often missing in ovarian cancers that become resistant to liposomal doxorubicin chemotherapy, hinting that it may serve as a marker for such acquired resistance.